Next Article in Journal
The Diverse Nature of the Molecular Interactions That Govern the COV-2 Variants’ Cell Receptor Affinity Ranking and Its Experimental Variability
Previous Article in Journal
The Predictive Value of Gut Microbiota Composition for Sustained Immunogenicity following Two Doses of CoronaVac
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 5
10.3390/ijms25052584
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Benzothiadiazinone-1,1-Dioxide Carbonic Anhydrase Inhibitors Suppress the Growth of Drug-Resistant Mycobacterium tuberculosis Strains

by
Silvia Bua
1,
Alessandro Bonardi
2,*,
Georgiana Ramona Mük
3,4,
Alessio Nocentini
2,*,
Paola Gratteri
2 and
Claudiu T. Supuran
2
1
Research Institute of the University of Bucharest (ICUB), University of Bucharest, 050095 Bucharest, Romania
2
Pharmaceutical and Nutraceutical Section, Laboratory of Molecular Modeling Cheminformatics & QSA, Neurofarba Department, University of Florence, Via U. Schiff 6, Sesto Fiorentino, 50019 Florence, Italy
3
Faculty of Biology, University of Bucharest, Splaiul Independenței 91-95, 050095 Bucharest, Romania
4
St. Stephen’s Pneumoftiziology Hospital, Șoseaua Ștefan cel Mare 11, 020122 Bucharest, Romania
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(5), 2584; https://doi.org/10.3390/ijms25052584
Submission received: 12 January 2024 / Revised: 19 February 2024 / Accepted: 20 February 2024 / Published: 23 February 2024
(This article belongs to the Special Issue Editorial Board Members’ Collection Series: “Bacterial Enzymes as Targets”)
Browse Figures
Versions Notes

Abstract

:
2H-Benzo[e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxide (BTD) based carbonic anhydrase (CA) inhibitors are here explored as new anti-mycobacterial agents. The chemical features of BTD derivatives meet the criteria for a potent inhibition of β-class CA isozymes. BTD derivatives show chemical features meeting the criteria for a potent inhibition of β-class CA isozymes. Specifically, three β-CAs (MtCA1, MtCA2, and MtCA3) were identified in Mycobacterium tuberculosis and their inhibition was shown to exert an antitubercular action. BTDs derivatives 2a-q effectively inhibited the mycobacterial CAs, especially MtCA2 and MtCA3, with Ki values up to a low nanomolar range (MtCA3, Ki = 15.1–2250 nM; MtCA2, Ki = 38.1–4480 nM) and with a significant selectivity ratio over the off-target human CAs I and II. A computational study was conducted to elucidate the compound structure-activity relationship. Importantly, the most potent MtCA inhibitors demonstrated efficacy in inhibiting the growth of M. tuberculosis strains resistant to both rifampicin and isoniazid—standard reference drugs for Tuberculosis treatment.

1. Introduction

Mycobacterium tuberculosis, also known as Koch bacillus, is the primary etiological agent responsible for the transmissible, chronic, and granulomatous infectious disease known as Tuberculosis (TB) [1]. In 2022 alone, this disease affected 10.6 million people and claimed the lives of 1.3 million individuals [1]. Among the infected population of all age groups, only 10% exhibit symptoms and are contagious [2]. Additionally, within this symptomatic group, only 50% survive with medical treatments [3].
TB primarily affects the lungs through the airborne transmission of bacteria when infected individuals cough, sneeze, or spit [4,5,6,7]. Upon entering the bloodstream, the bacteria can attack other organs and tissues, including the brain, kidneys, bones, spine, skin, peripheral lymph nodes, heart, pancreas, thyroid, spleen, eye, and skeletal muscles [8,9,10,11,12,13,14,15,16,17,18,19,20].
The common symptoms of TB vary depending on where in the body the infection becomes active and typically include a prolonged cough (sometimes with blood), chest pain, fatigue, weight loss, weakness, fever, and night sweats [1,4]. Several conditions, such as diabetes, a weakened immune system (e.g., HIV), malnutrition, and tobacco use, pose risk factors for Tuberculosis [21,22,23,24,25]. While the Bacille Calmette–Guérin (BCG) vaccine can be administered to infants or young children to prevent TB outside the lungs, it does not provide protection within the lungs [26]. Currently, the most effective vaccines are in phase I, II, and III of clinical trials [27,28,29,30]. Presently, the pharmacological treatment involves isoniazid and rifampicin for 4–6 months, representing the primary solution to combat TB infection [31,32].
Incorrect prescription or use of antibiotics, as well as premature therapy cessation, have led to the emergence of multidrug-resistant strains (MDR-TB) of M. tuberculosis against first-line drugs [33,34,35]. In such cases, second-line drugs like pyrazinamide, ethambutol, and streptomycin are employed [31,32]. However, anti-TB therapy shows serious side effects (e.g., hepatotoxicity) in almost 80% of the treated patients [36,37,38]. The ongoing research aims to develop more effective and safe medication to combat TB and MDR-TB [33,39].
Carbonic anhydrases (CAs, EC 4.2.1.1) constitute a superfamily of metalloenzymes that facilitate the reversible hydration of carbon dioxide into bicarbonate and a proton [40,41]. This reaction plays a crucial role in various physiological processes, including CO2 and HCO3− transport, electrolytic secretion, biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis), tumorigenesis (in vertebrates), photosynthesis (in plants and cyanobacteria), pH regulation, virulence, growth, and the acclimatization of pathogens in specific niches [40,41].
Among the eight non-correlated gene families of CAs (α, β, γ, δ, η, ζ, θ, and ι) discovered to date, α, β-, γ-, and ι-class CAs have been identified in bacteria [40,41]. the activity of bacterial CAs is essential for supporting microbial central metabolism by maintaining the correct balance of CO2 and HCO3−, and these enzymes are promising and currently validated antibacterial targets [41,42,43,44,45]. Consequently, inhibiting carbonic anhydrase with inhibitors (CAIs) disrupts the growth of microbes and impedes virulence processes that render a pathogenic bacterium infectious to the host.
Notably, three β-Cas (MtCA1, MtCA2, and MtCA3) have been found in M. tuberculosis, and their selective inhibition could lead to antitubercular activity, exploiting an innovative antibacterial mechanism [46]. In this context, the inhibition of the α-class humans (h) CAs must be avoided to prevent the onset of side effects.
The identification of selective chemotypes for bacterial and, specifically, mycobacterial CA inhibition is one of the recently explored approaches for addressing the challenge of multidrug resistance, which is increasingly pushing us ever closer to the risk of a post-antibiotic era [47,48,49].

2. Results and Discussion

2.1. Design and Chemistry

β-CAs have rather narrow and flat active sites compared to the conical ones of the α-CAs, with many residues nearby the Zn2+ ion (bound to 2 cysteines and 1 histidine) capable of forming an extended H-bond network [50,51]. Therefore, zinc-binding chemotypes, similar to sulfonamides, endowed with a planar geometry and the capability to form a number of H-bonds, might be a weapon in the research of selective β-CA inhibitors. To date, several compounds have been identified as effective inhibitors of the β-CAs from M. tuberculosis, among which sulfonamides [52] and dithiocarbamates [53] demonstrated the most promising effects, with no significant selectivity of action reported to date against mycobacterial CAs over human isozymes.
The 2H-benzo[e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxides 2a-2t (BTDs, Scheme 1) resulted from a preceding drug design for the development of antitumor CAIs, based on the hybridization of the scaffolds of two sweeteners, saccharin and acesulfame [54]. These compounds meet the aforementioned criteria for a potent binding to β-CAs and were never investigated earlier as inhibitors of bacterial CAs. Thus, they were re-prepared, according to the synthetic pathways of Scheme 1, to screen their β-CAs inhibitory action. As shown later in the article, potent and selective action against mycobacterial CAs was measured.
Briefly, the synthetic process involved the reaction of commercially available substituted anilines (1a-1n), N-methylanilines (1o,1p), and indoline (1q) with chlorosulfonyl isocyanate (CSI) at a temperature of −40 °C, utilizing nitroethane or nitromethane as a solvent. This reaction produced chlorosufamoyl urea intermediates βa-q. Subsequently, aluminum trichloride (AlCl3) was introduced, and the temperature was raised to 110 °C to facilitate a Friedel–Crafts-like core cyclization. The absence of a base and the maintenance of a very low temperature are crucial to preventing the aniline from reacting with the sulfamoyl portion of CSI. The choice between nitroethane and nitromethane is dictated by the need for a polar aprotic solvent that remains in a liquid state across a wide temperature range, from significantly below 0 °C to over 100 °C, without solidifying or boiling. Attempts to react markedly electron-poor anilines of the nitro-, sulfonamido-, or polyhalo-substituted types were unsuccessful due to their low reactivity in both reaction steps. Furthermore, the 5- and 7-methyl derivatives 2b and 2c underwent oxidation with potassium permanganate, yielding benzoic acids 2r and 2s, as depicted in Scheme 1. The 7-methoxy-BTD underwent demethylation upon treatment with 1.0 M BBr3 in DCM, resulting in the production of alcohol 2t (Scheme 1).

2.2. Carbonic Anhydrase Inhibition Assay

BTDs 2a-2t were submitted to a stopped-flow CO2 hydrase kinetic assay [55] to evaluate the inhibitory profile against the mycobacterial β-CAs MtCA1, MtCA2, MtCA3 (Table 1), in comparison to the inhibitory effect on hCA I and II, which were selected due to their abundance in the human organism and thus off-target in this study.
As observed in Table 1, derivatives 2a-2q effectively inhibited the investigated CA isozymes with Ki values ranging from 15.1 nM to greater than 10,000 nM. Notably, the most inhibited isozymes were MtCA3 (Ki = 15.1–2250 nM), MtCA2 (Ki = 38.1–4480 nM), hCA II (Ki = 140–6780 nM), MtCA1 (Ki = 556–>10,000 nM), and hCA I (Ki = 547–>10,000 nM), in descending order of potency.
Specifically, the incorporation of a methyl group (2b-2d) at positions 5 and/or 7 on the aromatic ring of the BTD scaffold variably enhances the inhibitory potency against MtCAs (2b > 2c > 2d), while diminishing the activity against hCAs. Conversely, a general weakening in inhibitory efficacy was noted for the 5,8- or 6,8-dimethyl substitutions (2e, 2f) among all investigated isozymes.
The substitution with a fluorine atom at position 5 (2g) improves inhibition against MtCA3 and weakly against MtCA1, whereas the 7-fluoro derivative 2h showed better Ki values only against MtCA2 than the unsubstituted compound 2a.
The introduction of bulkier substituents (2i-2m, 2r-2t), such as a chlorine/bromine atom or a methoxyl/carboxyl/hydroxyl group at positions 5 or 7, generally decreases inhibition against all investigated CAs compared to 2a, except for the 5-Cl (2i) and 5-Br (2k) substitutions, which enhance Ki values against MtCA1, and the 7-OH inclusion (2t), which increases the MtCA-2 inhibition.
The 5,6-benzo condensation in the BTD scaffold (2n) enhances MtCA1 inhibition, while its inhibitory profile decreases against all other investigated CAs.
Derivative 2o exhibits an increased inhibition profile against MtCA1 and 2, with a decreased Ki value against hCAs compared to 2a, which was attributed to the presence of a methyl group on the N4 atom. Moreover, the simultaneous introduction of 7-Cl (2p) or a ethylene connection (2q) enhances activity exclusively against MtCA-1.
All compounds showed a more potent inhibition of hCA II than hCA I, except for compounds 2f and 2t (Ki values in the micromolar range). The selectivity index of inhibition of MtCAs over hCA II, as the main off-target and inhibited human isozyme, was calculated and is reported in Table 2. Most BTDs exhibited a preferential action against the hCA II compared to MtCA1 (SI < 1), with the exception of the N-substituted 2o-2q and compounds 2s and 2t bearing hydrophilic substituents in position 7. In contrast, most BTDs demonstrated selectivity against MtCA2 and 3 over hCA II, ranging from 1.1 to 67. In detail, substituents appended at the 7 position of the scaffold promoted a higher selectivity of action compared to analog derivatives bearing a substitution in 5. This trend is even more marked for hCA II/MtCA3 (SI = 22.0–67.4) compared to hCA II/MtCA2 (SI = 11.8–51.8) selectivity. In fact, only a 5-substitution with a COOH moiety led to a SI hCA II/MtCA2 > 5. Instead, a greater number of 5-substituents lead to significant hCA II/MtCA2 SI (>5), such as a methyl, halogen, or carboxyl groups. It should also be noted that the N-methyl substitution (2o) improves the MtCA2 and 3 selectivity over hCA II.

2.3. In Silico Study

In silico studies were performed to thoroughly investigate the binding mode of BTDs 2a, 2c, 2d, 2h, and 2t within the active sites of the three β-Cas from M. tuberculosis. The aim was to unveil the relationship between the structural features and the inhibitory profile of the ligands. As the 3D-solved structure of MtCA3 is currently unavailable, we utilized the homology model (HM) previously built in our previous investigations [56,57].
In general, among the dimeric MtCAs active site, distinct structural variations contribute to a diverse binding mode of BTDs, explaining the different Ki values (Figure 1A–C).
Within the active sites of the three MtCAs, all docking solutions revealed the secondary sulfonamide bound to the zinc ion with the deprotonated nitrogen atom (SO2N−) adopting a tetrahedral geometry (Figure 1), consistent with the literature on the sulfonamides binding mode in the Cas active sites [40].
Furthermore, van der Waals (vdW) contacts with multiple hydrophobic residues play a significant role in reinforcing the metal binding coordination. These residues include M36(A), A59(A), G60(A), G92(A), M93(A), F96(A), M24(B), I73(B), L77(B), and L78(B) in MtCA1; A75(A), G75(A), G108(A), A109(A), A112(A), Q42(B), and Y89(B) in MtCA2; and Y603(A), L608(A), G609(A), A646(A), A647(A), M663(A), Q575(B), and F627(B) in MtCA3 (HM) (Figure 1, Figure 2, Figure 3 and Figure 4). In MtCA1, the orientation of the BTD scaffold is influenced by the steric hindrance of residues M93(A) and M24(B) (Figure 1A and Figure 2). Conversely, in MtCA2 and MtCA3 (HM), the crucial factors are π-π stacking interactions with Y89(B) and F627(B), respectively (Figure 1B,C, Figure 3 and Figure 4).
In the smaller active site of MtCA1, ligands 2a, 2c, 2d, 2h, and 2t exhibit a binding mode characterized by hydrophobic contacts and shape complementarity, achieved through distinct substituents on the aromatic ring (Figure 2). Substituents like hydrogens (2a), methyl groups (2c, 2d), or fluorine atoms (2h) are well accommodated (Figure 2A–D). Conversely, the tight cage lined by M93(A), T95(A), F96(A), M24(B), I73(B), L77(B), and L78(B) prevents the 8-substitution or the introduction of bulky groups (e.g., -Cl, -Br and -OCH3) or polar groups (e.g., -COOH and -OH (2t)) in position 5 or 7 (Figure 2E).
Within the MtCA2, the π-π stacking interaction between Y89(B) and the ligands aromatic ring, coupled with the M93(B)/A109(B) mutation (MtCA1/MtCA2), places the urea C=O of the BTD scaffold in H-bond distance with the backbone NH of G108(A) (Figure 3). The hydroxyl group of Y89(B) prevents the introduction of bulky groups in position 5 while allowing the 8-substitution with small groups. Additionally, the larger active site permits the hosting of larger or polar groups in position 7 of the aromatic ring (Figure 3B–E).
In the larger MtCA3 active site, the aromatic sidechain of F627(B) participates to a π-π stacking contact with the benzene ring of the ligands scaffold, allowing the formation of three H-bonds: one between the sulfonamide S=O and the backbone NH of G609(A), and two involving the other S=O group with the sidechains OH and NH2 of Y603(B) and Q575(B), respectively (Figure 4). The Y89(B)/F627(B) amino acid residues diversity between MtCA2/MtCA3 may thus be the explanation of the more effective inhibition profile of the 5-substituted ligands against the MtCA3 compared to the other MtCAs. Moreover, the roomier active site of MtCA3 better accommodates bulkier or polar substituent in position 7.
Despite the stabilizing effect of the I73(B)/Y89(B)/F627(B) mutation through π-π stacking within MtCA2 and MtCA3, it allows for the tolerance of substituents at position 8. In silico studies suggest that position 6 is the most favorable for functionalizing the 2H- BTD scaffold with larger pendants.
The ability of the BTD scaffold to establish strong interactions with MtCA3 > MtCA2 > MtCA1 elucidates the potent inhibition profile observed against MtCA3 and MtCA2 compared to MtCA1.

2.4. Tuberculostatic Activity Assay

Five of the most active compounds against MtCAs (2a, 2c, 2d, 2h, 2t) were selected to evaluate their in vitro tuberculostatic activity towards three distinct strains with varying susceptibility profiles to the first-line clinical drugs rifampicin and isoniazid. This evaluation was conducted following a 28-day incubation period at 37 °C. The selected strains included one susceptible to both rifampicin and isoniazid, one susceptible to rifampicin and resistant to isoniazid, and one resistant to both rifampicin and isoniazid (Table 2).
In detail, while only compounds 2c, 2d, 2h and the standard AAZ were active at the concentration of 1 µg/mL against the susceptible strain of M. tuberuculosis to rifampicin and isoniazid, all tested derivatives showed to inhibit the growth of mycobacteria at the increased concentration of 2 µg/mL. Except for 2t at a concentration of 1 µg/mL, all compounds have completely inhibited the growth of the M. tuberculosis strains resistant to isoniazid and susceptible to rifampicin. Remarkably, all tested substances have inhibited the growth of the M. tuberculosis strain resistant to rifampicin and isoniazid at both concentrations (Table 3).

3. Material and Methods

3.1. Chemistry

Materials, methods, and synthetic procedures were previously reported [53].

3.2. Carbonic Anhydrase CO2 Hydration Catalytic/Inhibition Assay and Ki Determination

A stopped-flow instrument from Applied Photophysics was utilized to assess the inhibition of CA-catalyzed CO2 hydration activity [55]. Phenol red, present at a concentration of 0.2 mM, served as an indicator and operated at the absorbance peak of 557 nm. The assay employed 20 mM HEPES (pH 8.3) as a buffer and 20 mM Na2SO4 to maintain constant ionic strength. The investigation focused on the initial rates of the CA-catalyzed CO2 hydration reaction over a duration of 10–100 s. CO2 concentrations ranging from 1.7 to 17 mM were employed to determine kinetic parameters and inhibition constants. For each inhibitor, a minimum of six traces of the initial 5–10% of the reaction were utilized to determine the initial velocity. Uncatalyzed rates were determined in a similar manner and subtracted from the overall observed rates. Inhibitor stock solutions (0.1 mM) were initially prepared in distilled–deionized water, followed by subsequent dilutions up to 0.01 nM with the assay buffer. To allow for the formation of the E-I complex, inhibitor and enzyme solutions were preincubated together for 15 min at room temperature before the assay. The inhibition constants were derived through nonlinear least-squares methods using PRISM and the Cheng–Prusoff equation, as previously reported [51], representing the mean from at least three different determinations. Enzyme concentrations fell within the range of 6 to 19 nM, and all CA isoforms used were recombinant and obtained in-house, as detailed earlier [46].

3.3. In Silico Studies

The UniProt consortium was used to obtain the primary sequence of MtCA3. The homology modelling procedure used the 3D solved structure of β-CA from Synechocystis sp. PCC 6803 (PDB code 5SWC; resolution 1.45 Å) [58] as a template [56]. A large number of models were generated using the Prime module of Schrödinger [59] and the SwissModel platform [60]. These models were subjected to loop refinement and quality assessment procedures [56]. The highest scoring structure of MtCA3 and the crystal structures of CA I (PDB code 2NMX) [61], CA II (PDB code 3K34) [62], MtCA1 (PDB code 1YLK) [63], and MtCA2 (PDB code 2A5V) [64], downloaded from the Protein Data Bank (RCSB.org) [65], were prepared using the Protein Preparation module of the Maestro Schrödinger suite [60]. This involved the assignment of bond orders, the addition of hydrogens, the deletion of water molecules and the optimization of H-bond networks. The structures were then energy minimized to a Root Means Square Deviation (RMSD) of 0.30 using the Optimized Potential for Liquid Simulation (OPLS4) force field [66,67]. The 3D ligand structures were generated using Maestro [59]. The ionization states at pH 7.3 ± 1.0 were evaluated using Epik [59]. Energy minimization was performed using the conjugate gradient method in Macromodel [59] with a maximum iteration number of 2500 and a convergence criterion of 0.05 Kcal/mol/Å2. Docking studies were performed using the Glide program [59] in Standard Precision (SP) mode, with docking grids centered on the centroid of the complexed ligand. The resulting figures were generated using Chimera and Maestro [59,68].

3.4. Tuberculostatic Activity Assay

The tuberculostatic efficacy was evaluated against three different strains of M. tuberculosis, each exhibiting distinct susceptibility profiles—one susceptible to both rifampicin and isoniazid, another susceptible to rifampicin but resistant to isoniazid, and a third resistant to both rifampicin and isoniazid. The examined compounds were integrated into Lowenstein Jensen (LJ) solid medium at concentrations of 1 and 2 μg/mL. The tubes were positioned at a 45° angle in a thermostat set at 37 °C, ensuring the distribution of the tested substances within the culture medium. After 48 h, the inoculum was seeded onto the respective tubes, and the tubes were then incubated for 28 days. Simultaneously, the inoculum was also seeded onto a control tube that lacked the tested substances. To verify the sterility of the culture medium and the tested substances, unseeded samples were kept in the thermostat at 37 °C and observed for 28 days to confirm the absence of any growth or contamination. Following the 28-day incubation period, the colonies on media supplemented with varying concentrations of the tested substance were counted, along with colonies on the control tubes (one tube for each experiment). To ensure the validity of the results, it was crucial that numerous but countable colonies developed on the control tubes after 28 days of incubation. Result interpretation followed the absolute concentration method, where the growth of <30 colonies was deemed susceptible, while >30 colonies indicated resistance to the respective substance [69].

4. Conclusions

BTD-based CA inhibitors were investigated as novel anti-mycobacterial agents. The BTD framework aligns with the criteria identified for effectively inhibiting β-class CA isozymes. The three β-CAs (MtCA1, MtCA2, and MtCA3) encoded by M. tubercolisis play a pivotal role for the pathogen growth and virulence, and inhibiting them has demonstrated significant anti-tubercular effects. BTD derivatives 2a-q have proven to be potent inhibitors of mycobacterial CAs, particularly MtCA2 and MtCA3, exhibiting Ki values in the low nanomolar range (MtCA3, Ki = 15.1–2254 nM; MtCA2, Ki = 38.1–4482 nM). Notably, these derivatives show a substantial selectivity ratio over human off-target CAs I and II. To better understand the structure-activity relationship of these BTD CA inhibitors, a comprehensive computational study was conducted. Crucially, the most effective MtCA inhibitors—2a, 2c, 2d, 2h, 2t, inhibited—the growth of M. tuberculosis strains resistant to both rifampicin and isoniazid, standard drugs in Tuberculosis treatment. This underscores the potential of BTD derivatives as promising candidates for the development of innovative anti-mycobacterial agents, emphasizing their ability to selectively target specific CA isozymes crucial for the survival of M. tuberculosis.

Author Contributions

Conceptualization, A.B. and A.N.; methodology, A.B.; software, P.G.; formal analysis, S.B. and A.B.; investigation, S.B., A.B. and G.R.M.; data curation, A.B., A.N. and P.G.; writing—original draft preparation, A.B.; writing—review and editing, A.N., P.G. and C.T.S.; visualization, funding acquisition, C.T.S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was partially supported by a grant from the Italian Ministry of University and Research for financial support under the FISR program, project FISR_04819 BacCAD to C.T.S. S.B. acknowledges the Research Institute of the University of Bucharest for the ICUB Fellowship for Young Researchers.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data will be made available on request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. World Health Organization. Global Tuberculosis Report 2023; Licence: CC BY-NC-SA 3.0 IGO; World Health Organization: Geneva, Switzerland, 2023. Available online: https://www.who.int/publications/i/item/9789240083851 (accessed on 12 December 2023).
  2. Alsayed, S.S.R.; Gunosewoyo, H. Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. Int. J. Mol. Sci. 2023, 24, 5202. [Google Scholar] [CrossRef] [PubMed]
  3. Flynn, J.L.; Chan, J. Tuberculosis: Latency and Reactivation. Infect. Immun. 2001, 69, 4195–4201. [Google Scholar] [CrossRef]
  4. Pai, M.; Behr, M.A.; Dowdy, D.; Dheda, K.; Divangahi, M.; Boehme, C.C.; Ginsberg, A.; Swaminathan, S.; Spigelman, M.; Getahun, H.; et al. Tuberculosis. Nat. Rev. Dis. Primers 2016, 27, 16076. [Google Scholar] [CrossRef] [PubMed]
  5. Chandra, P.; Grigsby, S.J.; Philips, J.A. Immune evasion and provocation by Mycobacterium tuberculosis. Nat. Rev. Microbiol. 2022, 20, 750–766. [Google Scholar] [CrossRef] [PubMed]
  6. Philips, J.A.; Ernst, J.D. Tuberculosis Pathogenesis and Immunity. Annu. Rev. Pathol. Mech. Dis. 2012, 7, 353–384. [Google Scholar] [CrossRef] [PubMed]
  7. Acharya, B.; Acharya, A.; Gautam, S.; Ghimire, S.P.; Mishra, G.; Parajuli, N.; Sapkota, B. Advances in diagnosis of Tuberculosis: An update into molecular diagnosis of Mycobacterium tuberculosis. Mol. Biol. Rep. 2020, 47, 4065–4075. [Google Scholar] [CrossRef]
  8. McMahon, P.; Pisapia, D.J.; Schweitzer, A.D.; Heier, L.; Souweidane, M.M.; Roytman, M. Central nervous system tuberculoma mimicking a brain tumor: A case report. Radiol. Case Rep. 2023, 19, 414–417. [Google Scholar] [CrossRef]
  9. Daher Ede, F.; da Silva, G.B., Jr.; Barros, E.J. Renal tuberculosis in the modern era. Am. J. Trop. Med. Hyg. 2013, 88, 54–64. [Google Scholar] [CrossRef]
  10. Shaikh, G.A.; Yaqoob, S.; Batool, F.; Waseem, R.; Shah, H.H.; Abbasi, A.A.; Lashari, N.; Dave, T. A rare case of tuberculous myocarditis: A diagnostic challenge in a tuberculosis-endemic country. Clin. Case Rep. 2023, 11, e8224. [Google Scholar] [CrossRef]
  11. Chen, B.; Bao, Y.; Chen, J.; Zhang, Y.; Wen, Q.; Wang, K.; Cheng, X.; Lv, J. Isolated soft tissue tuberculosis: A case report and literature review. Front. Med. 2023, 10, 1205446. [Google Scholar] [CrossRef] [PubMed]
  12. Baidya, A.; Singha, A.; Bhattacharjee, R.; Dalal, B.S. Tuberculosis of the thyroid gland: Two case reports. Oxf. Med. Case Rep. 2015, 2015, 262–264. [Google Scholar] [CrossRef] [PubMed]
  13. Ganchua, S.K.C.; White, A.G.; Klein, E.C.; Flynn, J.L. Lymph nodes-The neglected battlefield in tuberculosis. PLoS Pathog. 2020, 16, e1008632. [Google Scholar] [CrossRef] [PubMed]
  14. Shaikh, O.H.; Sunil, J.; Prakash, S.; Vijaykumar, C.; Kumbhar, U.S. Isolated pancreatic tuberculosis masquerading pancreatic malignancy. BMJ Case Rep. 2023, 16, e254250. [Google Scholar] [CrossRef] [PubMed]
  15. Salih, A.M.; Qaradakhy, A.J.; Hassan, S.H.; Abdullah, A.M.; Dhahir, H.M.; Karim, S.O.; Sofi, H.A.; Abdalla, B.A.; Ali, M.H.; Kakamad, F.H. Tuberculous granulomatous inflammation of parathyroid adenoma manifested as primary hyperparathyroidism: A case report and a review of the literature. Med. Int. 2023, 3, 49. [Google Scholar] [CrossRef]
  16. Gadde, A.B.; Jha, P.K.; Bansal, S.B.; Rana, A.; Jain, M.; Bansal, D.; Yadav, D.K.; Mahapatra, A.K.; Sethi, S.K.; Kher, V. Renal Transplantation in Patients with Tuberculosis: A Single-center Experience from an Endemic Region. Transplant. Direct 2023, 9, e1541. [Google Scholar] [CrossRef]
  17. Malihy, Z.; Benaissa, E.; Ben Lahlou, Y.; Maleb, A.; Elouennass, M. Osteoarticular tuberculosis of the ankle, a rare localization: A case report. Access Microbiol. 2023, 5, 000654.v3. [Google Scholar] [CrossRef]
  18. Tsui, J.K.; Poon, S.H.L.; Fung, N.S.K. Ocular manifestations and diagnosis of tuberculosis involving the uvea: A case series. Trop. Dis. Travel Med. Vaccines 2023, 9, 20. [Google Scholar] [CrossRef]
  19. Singh, A.; Singh, B.K.; Singh, V.K.; Nagarajan, S. Presumptive ocular tuberculosis: A case series of rare cases. Oman J. Ophthalmol. 2023, 16, 529–532. [Google Scholar]
  20. Pottakkat, B.; Kumar, A.; Rastogi, A.; Krishnani, N.; Kapoor, V.K.; Saxena, R. Tuberculosis of the spleen as a cause of Fever of unknown origin and splenomegaly. Gut Liver 2010, 4, 94–97. [Google Scholar] [CrossRef]
  21. Rehman, A.U.; Khattak, M.; Mushtaq, U.; Latif, M.; Ahmad, I.; Rasool, M.F.; Shakeel, S.; Hayat, K.; Hussain, R.; Alhazmi, G.A.; et al. The impact of diabetes mellitus on the emergence of multi-drug resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: A systematic review and meta-analysis. Front. Public Health 2023, 11, 1244450. [Google Scholar] [CrossRef]
  22. Mbewana Ntshanka, N.G.; Msagati, T.A.M. Trends and Progress on Antibiotic-Resistant Mycobacterium tuberculosis and Genes in relation to Human Immunodeficiency Virus. Can. J. Infect. Dis. Med. Microbiol. 2023, 2023, 6659212. [Google Scholar] [CrossRef]
  23. Lall, D. Tuberculosis and undernutrition in India. Lancet Glob. Health 2023, 11, e1859. [Google Scholar] [CrossRef]
  24. Wagnew, F.; Alene, K.A.; Kelly, M.; Gray, D. Geospatial Overlap of Undernutrition and Tuberculosis in Ethiopia. Int. J. Environ. Res. Public Health 2023, 20, 7000. [Google Scholar] [CrossRef]
  25. Corleis, B.; Tzouanas, C.N.; Wadsworth, M.H., 2nd; Cho, J.L.; Linder, A.H.; Schiff, A.E.; Zessin, B.; Stei, F.; Dorhoi, A.; Dickey, A.K.; et al. Tobacco smoke exposure recruits inflammatory airspace monocytes that establish permissive lung niches for Mycobacterium tuberculosis. Sci. Transl. Med. 2023, 15, eadg3451. [Google Scholar] [CrossRef] [PubMed]
  26. Boisson-Walsh, A.; Thompson, P.; Fried, B.; Shea, C.M.; Ngimbi, P.; Lumande, F.; Tabala, M.; Kashamuka, M.M.; Babakazo, P.; Domino, M.E.; et al. Childhood immunization uptake determinants in Kinshasa, Democratic Republic of the Congo: Ordered regressions to assess timely infant vaccines administered at birth and 6-weeks. Glob. Health Res. Policy 2023, 8, 50. [Google Scholar] [CrossRef]
  27. Cotton, M.F.; Rabie, H. Planning to introduce novel tuberculosis vaccines in high burden settings: How could this be done? Lancet Glob. Health 2023, 11, e484–e485. [Google Scholar] [CrossRef]
  28. Tait, D.R.; Hatherill, M.; Van Der Meeren, O.; Ginsberg, A.M.; Van Brakel, E.; Salaun, B.; Scriba, T.J.; Akite, E.J.; Ayles, H.M.; Bollaerts, A.; et al. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N. Engl. J. Med. 2019, 381, 2429–2439. [Google Scholar] [CrossRef]
  29. Blossey, A.M.; Brückner, S.; May, M.; Parzmair, G.P.; Sharma, H.; Shaligram, U.; Grode, L.; Kaufmann, S.H.E.; Netea, M.G.; Schindler, C. VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study. Clin. Infect. Dis. 2023, 76, 1304–1310. [Google Scholar] [CrossRef] [PubMed]
  30. Tkachuk, A.P.; Bykonia, E.N.; Popova, L.I.; Kleymenov, D.A.; Semashko, M.A.; Chulanov, V.P.; Fitilev, S.B.; Maksimov, S.L.; Smolyarchuk, E.A.; Manuylov, V.A.; et al. Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. Vaccines 2020, 8, 652. [Google Scholar] [CrossRef] [PubMed]
  31. Pereira, L.; Marco-García, M.; Gamell, A.; Cusó, T.; Monsonís, M.; Latre, C.; Fortuny, C.; Noguera-Julian, A. Toxicity of the Increased Recommended Doses of First-line Anti-tuberculosis Oral Drugs in Children in a Reference Center in Spain. Arch. Bronconeumol. 2023, 59, 612–615. [Google Scholar] [CrossRef] [PubMed]
  32. Ndambuki, J.; Nzomo, J.; Muregi, L.; Mutuku, C.; Makokha, F.; Nthusi, J.; Ambale, C.; Lynen, L.; Decroo, T. Comparison of first-line tuberculosis treatment outcomes between previously treated and new patients: A retrospective study in Machakos subcounty, Kenya. Int. Health 2021, 13, 272–280. [Google Scholar] [CrossRef] [PubMed]
  33. World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment—Drug-Resistant Tuberculosis Treatment, 2022 Update; Licence: CC BY-NC-SA 3.0 IGO; World Health Organization: Geneva, Switzerland, 2022. Available online: https://www.who.int/publications/i/item/9789240063129 (accessed on 12 December 2023).
  34. Tiberi, S.; Utjesanovic, N.; Galvin, J.; Centis, R.; D’Ambrosio, L.; van den Boom, M.; Zumla, A.; Migliori, G.B. Drug resistant TB—Latest developments in epidemiology, diagnostics and management. Int. J. Infect. Dis. 2022, 124, S20–S25. [Google Scholar] [CrossRef] [PubMed]
  35. Seung, K.J.; Keshavjee, S.; Rich, M.L. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb. Perspect. Med. 2015, 5, a017863. [Google Scholar] [CrossRef] [PubMed]
  36. Akkahadsee, P.; Sawangjit, R.; Phumart, P.; Chaiyakunapruk, N.; Sakloetsakun, D. Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury. Sci. Rep. 2023, 13, 19880. [Google Scholar] [CrossRef] [PubMed]
  37. Molla, Y.; Wubetu, M.; Dessie, B. Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia. Hepatic Med. 2021, 13, 1–8. [Google Scholar] [CrossRef]
  38. Sekaggya-Wiltshire, C.; von Braun, A.; Scherrer, A.U.; Manabe, Y.C.; Buzibye, A.; Muller, D.; Ledergerber, B.; Gutteck, U.; Corti, N.; Kambugu, A.; et al. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. J. Antimicrob. Chemother. 2017, 72, 1172–1177. [Google Scholar] [CrossRef]
  39. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2022; Licence: CC BY-NC-SA 3.0 IGO; World Health Organization: Geneva, Switzerland, 2022. Available online: https://www.who.int/publications/i/item/9789240062702 (accessed on 12 December 2023).
  40. Mishra, C.B.; Tiwari, M.; Supuran, C.T. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today? Med. Res. Rev. 2020, 40, 2485–2565. [Google Scholar] [CrossRef]
  41. Supuran, C.T.; Capasso, C. Antibacterial carbonic anhydrase inhibitors: An update on the recent literature. Expert Opin. Ther. Pat. 2020, 30, 963–982. [Google Scholar] [CrossRef]
  42. Kaur, J.; Cao, X.; Abutaleb, N.S.; Elkashif, A.; Graboski, A.L.; Krabill, A.D.; AbdelKhalek, A.H.; An, W.; Bhardwaj, A.; Seleem, M.N.; et al. Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus. J. Med. Chem. 2020, 63, 9540–9562. [Google Scholar] [CrossRef]
  43. Abutaleb, N.S.; Elhassanny, A.E.M.; Flaherty, D.P.; Seleem, M.N. In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ 2021, 9, e11059. [Google Scholar] [CrossRef]
  44. Abutaleb, N.S.; Elhassanny, A.E.M.; Seleem, M.N. In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection. Microb. Pathog. 2022, 164, 105454. [Google Scholar] [CrossRef] [PubMed]
  45. Abuaita, B.H.; Withey, J.H. Bicarbonate Induces Vibrio cholerae virulence gene expression by enhancing ToxT activity. Infect. Immun. 2009, 77, 4111–4120. [Google Scholar] [CrossRef]
  46. Aspatwar, A.; Kairys, V.; Rala, S.; Parikka, M.; Bozdag, M.; Carta, F.; Supuran, C.T.; Parkkila, S. Mycobacterium tuberculosis β-Carbonic Anhydrases: Novel Targets for Developing Antituberculosis Drugs. Int. J. Mol. Sci. 2019, 20, 5153. [Google Scholar] [CrossRef] [PubMed]
  47. Kwon, J.H.; Powderly, W.G. The post-antibiotic era is here. Science 2021, 373, 471. [Google Scholar] [CrossRef] [PubMed]
  48. Cima, G. WHO warns of ‘post-antibiotic era’. J. Am. Vet. Med. Assoc. 2014, 244, 1356–1357. [Google Scholar]
  49. Zucca, M.; Savoia, D. The post-antibiotic era: Promising developments in the therapy of infectious diseases. Int. J. Biomed. Sci. 2010, 6, 77–86. [Google Scholar]
  50. Nocentini, A.; Cadoni, R.; Del Prete, S.; Capasso, C.; Dumy, P.; Gratteri, P.; Supuran, C.T.; Winum, J.Y. Benzoxaboroles as Efficient Inhibitors of the β-Carbonic Anhydrases from Pathogenic Fungi: Activity and Modeling Study. ACS Med. Chem. Lett. 2017, 8, 1194–1198. [Google Scholar] [CrossRef]
  51. Bonardi, A.; Nocentini, A.; Cadoni, R.; Del Prete, S.; Dumy, P.; Capasso, C.; Gratteri, P.; Supuran, C.T.; Winum, J.Y. Benzoxaboroles: New Potent Inhibitors of the Carbonic Anhydrases of the Pathogenic Bacterium Vibrio cholerae. ACS Med. Chem. Lett. 2020, 11, 2277–2284. [Google Scholar] [CrossRef]
  52. Güzel, O.; Maresca, A.; Scozzafava, A.; Salman, A.; Balaban, A.T.; Supuran, C.T. Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. J. Med. Chem. 2009, 52, 4063–4067. [Google Scholar] [CrossRef]
  53. Aspatwar, A.; Hammarén, M.; Koskinen, S.; Luukinen, B.; Barker, H.; Carta, F.; Supuran, C.T.; Parikka, M.; Parkkila, S. beta-CA-specific inhibitor dithiocarbamate Fc14-584B: A novel antimycobacterial agent with potential to treat drug-resistant tuberculosis. J. Enzym. Inhib. Med. Chem. 2017, 32, 832–840. [Google Scholar] [CrossRef]
  54. Bua, S.; Lomelino, C.; Murray, A.B.; Osman, S.M.; ALOthman, Z.A.; Bozdag, M.; Abdel-Aziz, H.A.; Eldehna, W.M.; McKenna, R.; Nocentini, A.; et al. “A Sweet Combination”: Developing Saccharin and Acesulfame K Structures for Selectively Targeting the Tumor-Associated Carbonic Anhydrases IX and XII. J. Med. Chem. 2020, 63, 321–333. [Google Scholar] [CrossRef] [PubMed]
  55. Khalifah, R.G. The carbon dioxide hydration activity of carbonic anhydrase I. Stop-flow kinetic studies on the native human isoenzymes B and C. J. Biol. Chem. 1971, 246, 2561–2573. [Google Scholar] [CrossRef] [PubMed]
  56. Abdoli, M.; Bonardi, A.; Paoletti, N.; Aspatwar, A.; Parkkila, S.; Gratteri, P.; Supuran, C.T.; Žalubovskis, R. Inhibition Studies on Human and Mycobacterial Carbonic Anhydrases with N-((4-Sulfamoylphenyl)carbamothioyl) Amides. Molecules 2023, 28, 4020. [Google Scholar] [CrossRef] [PubMed]
  57. Ommi, O.; Paoletti, N.; Bonardi, A.; Gratteri, P.; Bhalerao, H.A.; Sau, S.; Nanduri, S.; Mohammed, A.; Kalia, N.P.; Sonti, R.; et al. Exploration of 3-aryl pyrazole-tethered sulfamoyl carboxamides as carbonic anhydrase inhibitors. Arch. Pharm. 2023, 356, e2300309. [Google Scholar] [CrossRef] [PubMed]
  58. McGurn, L.D.; Moazami-Goudarzi, M.; White, S.A.; Suwal, T.; Brar, B.; Tang, J.Q.; Espie, G.S.; Kimber, M.S. The structure, kinetics and interactions of the β-carboxysomal β-carbonic anhydrase, CcaA. Biochem. J. 2016, 473, 4559–4572. [Google Scholar] [CrossRef] [PubMed]
  59. Schrödinger Suite Release 2022-4, Schrödinger, LLC, New York, NY, 2022: (a) Prime, v.5.5; (b) Maestro v.13.2; (c) Epik, v.6.0; (d) Impact, v.9.5; (e) Macromodel v.13.6. (f) Glide, v.9.5.
  60. Waterhouse, A.; Bertoni, M.; Bienert, S.; Studer, G.; Tauriello, G.; Gumienny, R.; Heer, F.T.; de Beer, T.A.P.; Rempfer, C.; Bordoli, L.; et al. SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res. 2018, 46, W296–W303. [Google Scholar] [CrossRef] [PubMed]
  61. Srivastava, D.K.; Jude, K.M.; Banerjee, A.L.; Haldar, M.; Manokaran, S.; Kooren, J.; Mallik, S.; Christianson, D.W. Structural analysis of charge discrimination in the binding of inhibitors to human carbonic anhydrases I and II. J. Am. Chem. Soc. 2007, 129, 5528–5537. [Google Scholar] [CrossRef]
  62. Behnke, C.A.; Le Trong, I.; Godden, J.W.; Merritt, E.A.; Teller, D.C.; Bajorath, J.; Stenkamp, R.E. Atomic resolution studies of carbonic anhydrase II. Acta Crystallogr. Sect. D Biol. Crystallogr. 2010, 66, 616–627. [Google Scholar] [CrossRef]
  63. Suarez Covarrubias, A.; Larsson, A.M.; Högbom, M.; Lindberg, J.; Bergfors, T.; Björkelid, C.; Mowbray, S.L.; Unge, T.; Jones, T.A. Structure and function of carbonic anhydrases from Mycobacterium tuberculosis. J. Biol. Chem. 2005, 280, 18782–18789. [Google Scholar] [CrossRef]
  64. Covarrubias, A.S.; Bergfors, T.; Jones, T.A.; Högbom, M. Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis. J. Biol. Chem. 2006, 281, 4993–4999. [Google Scholar] [CrossRef]
  65. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235–242. [Google Scholar] [CrossRef]
  66. Lu, C.; Wu, C.; Ghoreishi, D.; Chen, W.; Wang, L.; Damm, W.; Ross, G.A.; Dahlgren, M.K.; Russell, E.; Von Bargen, C.D.; et al. OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space. J. Chem. Theory Comput. 2021, 17, 4291–4300. [Google Scholar] [CrossRef] [PubMed]
  67. Kaminski, G.A.; Friesner, R.A.; Tirado-Rives, J.; Jorgensen, W.L. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides. J. Phys. Chem. B 2001, 105, 6474–6487. [Google Scholar] [CrossRef]
  68. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef] [PubMed]
  69. Homorodean, D.; Moisoiu, A.; Borroni, E. Ghid Național Pentru Rețeaua Laboratoarelor TB; Ministerul Sănătății: Bucharest, Romania, 2017. [Google Scholar]
Ijms 25 02584 sch001
Scheme 1. Synthesis of 2H-benzo[e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxides 2a-2t [54].
Scheme 1. Synthesis of 2H-benzo[e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxides 2a-2t [54].
Ijms 25 02584 sch001
Ijms 25 02584 g001
Figure 1. 2D-Schematic representation of the binding mode of BTDs within the (A) MtCA1, (B) MtCA2, and (C) MtCA3 (HM) active site. The labels of amino acids from different chains are colored differently (Chain A: black, Chain B: blue).
Figure 1. 2D-Schematic representation of the binding mode of BTDs within the (A) MtCA1, (B) MtCA2, and (C) MtCA3 (HM) active site. The labels of amino acids from different chains are colored differently (Chain A: black, Chain B: blue).
Ijms 25 02584 g001
Ijms 25 02584 g002
Figure 2. Predicted binding mode of ligands (A) 2a (cyan), (B) 2c (orange), (C) 2d (green), (D) 2h (purple) and (E) 2t (gold) within the MtCA1 active site (pdb 1YLK). H-bonds are represented as black dashed lines, respectively. The labels of amino acids from different chains are colored differently (Chain A: black, Chain B: blue).
Figure 2. Predicted binding mode of ligands (A) 2a (cyan), (B) 2c (orange), (C) 2d (green), (D) 2h (purple) and (E) 2t (gold) within the MtCA1 active site (pdb 1YLK). H-bonds are represented as black dashed lines, respectively. The labels of amino acids from different chains are colored differently (Chain A: black, Chain B: blue).
Ijms 25 02584 g002
Ijms 25 02584 g003
Figure 3. Predicted binding mode of ligands (A) 2a (cyan), (B) 2c (orange), (C) 2d (green), (D) 2h (purple), and (E) 2t (gold) within the MtCA2 active site (pdb 2A5V). H-bonds and π-π stackings are represented as black and cyan dashed lines, respectively. The labels of amino acids from different chains are colored differently (Chain A: black, Chain B: blue).
Figure 3. Predicted binding mode of ligands (A) 2a (cyan), (B) 2c (orange), (C) 2d (green), (D) 2h (purple), and (E) 2t (gold) within the MtCA2 active site (pdb 2A5V). H-bonds and π-π stackings are represented as black and cyan dashed lines, respectively. The labels of amino acids from different chains are colored differently (Chain A: black, Chain B: blue).
Ijms 25 02584 g003
Ijms 25 02584 g004
Figure 4. Predicted binding mode of ligands (A) 2a (cyan), (B) 2c (orange), (C) 2d (green), (D) 2h (purple), and (E) 2t (gold) within the MtCA3 (HM) active site. H-bonds and π-π stackings are represented as black and cyan dashed lines, respectively. The labels of amino acids from different chains are colored differently (Chain A: black, Chain B: blue).
Figure 4. Predicted binding mode of ligands (A) 2a (cyan), (B) 2c (orange), (C) 2d (green), (D) 2h (purple), and (E) 2t (gold) within the MtCA3 (HM) active site. H-bonds and π-π stackings are represented as black and cyan dashed lines, respectively. The labels of amino acids from different chains are colored differently (Chain A: black, Chain B: blue).
Ijms 25 02584 g004
Table 1. Inhibition data of β-CAs from M. tuberculosis (MtCA1, MtCA2, MtCA3) and human CA isozymes I and II with compounds 2a-2t and acetazolamide (AAZ) as a standard drug, by a stopped-flow CO2 hydrase assay [55].
Table 1. Inhibition data of β-CAs from M. tuberculosis (MtCA1, MtCA2, MtCA3) and human CA isozymes I and II with compounds 2a-2t and acetazolamide (AAZ) as a standard drug, by a stopped-flow CO2 hydrase assay [55].
Ijms 25 02584 i001
Ki (nM) a
CmpdRR1MtCA1MtCA2MtCA3hCA I bhCA II b
2aHH1680 ± 9368.6 ± 3.128.7 ± 2.1866150
2b5-CH3H1460 ± 10158.5 ± 1.721.3 ± 1.7969144
2c7-CH3H1050 ± 6541.3 ± 2.018.5 ± 1.61070872
2d5,7-diCH3H934 ± 7838.1 ± 1.115.1 ± 0.91270764
2e5,8-diCH3H>10,0002370 ± 1671540 ± 9125402190
2f6,8-diCH3H>10,0004480 ± 2772250 ± 16819202940
2g5-FH1290 ± 9662.9 ± 2.516.2 ± 1.1547140
2h7-FH1830 ± 13742.5 ± 1.624.3 ± 1.41290534
2i5-ClH1500 ± 89214 ± 1344.3 ± 2.9930686
2j7-ClH2460 ± 17467.1 ± 4.339.8 ± 2.218601140
2k5-BrH993 ± 33458 ± 2582.4 ± 4.92320527
2l7-BrH2960 ± 213200 ± 1490.1 ± 6.744002360
2m7-OCH3H2760 ± 166152 ± 1159.2 ± 4.238101920
2n5,6-benzoH1040 ± 41995 ± 35120 ± 82070484
2oHCH3556 ± 3739.6 ± 2.132.5 ± 2.43410853
2p7-ClCH31180 ± 75135 ± 946.0 ± 3.3>10,0002340
2q5-CH2-CH2-883 ± 24 599 ± 3176.2 ± 5.668601060
2r5-COOHH3280 ± 204105 ± 665.4 ± 3.957802450
2s7-COOHH4870 ± 315223 ± 18101 ± 5>10,0006780
2t7-OHH2390 ± 12658.4 ± 4.145.6 ± 3.518903020
AAZ-4809.810425012.5
a Mean from three different assays, by a stopped-flow technique (errors were in the range of ±5–10% of the reported values); b Ki values from Ref. [54].
Table 2. Selective index (SI) for BTD compounds calculated as ratio between Ki against MtCAs and hCA II, as the main off-target isozyme.
Table 2. Selective index (SI) for BTD compounds calculated as ratio between Ki against MtCAs and hCA II, as the main off-target isozyme.
Ijms 25 02584 i002
Selectivity Index (SI)
CmpdRR1hCA II/MtCA1hCA II/MtCA2hCA II/MtCA3
2aHH0.12.25.2
2b5-CH3H0.12.56.8
2c7-CH3H0.821.147.1
2d5,7-diCH3H0.820.050.6
2e5,8-diCH3H<0.20.91.4
2f6,8-diCH3H<0.30.71.3
2g5-FH0.12.28.6
2h7-FH0.312.622.0
2i5-ClH0.53.215.5
2j7-ClH0.517.028.7
2k5-BrH0.51.16.4
2l7-BrH0.811.826.2
2m7-OCH3H0.712.632.5
2n5,6-benzoH0.50.54.0
2oHCH31.521.526.2
2p7-ClCH32.017.350.8
2q5-CH2-CH2-1.21.813.9
2r5-COOHH0.723.237.4
2s7-COOHH1.430.467.4
2t7-OHH1.351.866.3
AAZ-<0.11.30.1
Table 3. The number of M. tuberculosis colonies/standard inoculum volume (0.2 mL) recovered from the culture medium supplemented with different concentrations of the tested substances.
Table 3. The number of M. tuberculosis colonies/standard inoculum volume (0.2 mL) recovered from the culture medium supplemented with different concentrations of the tested substances.
Strain Susceptible to Rifampicin and IsoniazidStrain Resistant to IsoniazidStrain Resistant to Both Rifampicin and Isoniazid
Cmpd1 µg/mL2 µg/mL1 µg/mL2 µg/mL1 µg/mL2 µg/mL
2a3000000
2c000000
2d000000
2h000000
2t30–100030–100000
MTZ30–10000000
AAZ000000
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Bua, S.; Bonardi, A.; Mük, G.R.; Nocentini, A.; Gratteri, P.; Supuran, C.T. Benzothiadiazinone-1,1-Dioxide Carbonic Anhydrase Inhibitors Suppress the Growth of Drug-Resistant Mycobacterium tuberculosis Strains. Int. J. Mol. Sci. 2024, 25, 2584. https://doi.org/10.3390/ijms25052584

AMA Style

Bua S, Bonardi A, Mük GR, Nocentini A, Gratteri P, Supuran CT. Benzothiadiazinone-1,1-Dioxide Carbonic Anhydrase Inhibitors Suppress the Growth of Drug-Resistant Mycobacterium tuberculosis Strains. International Journal of Molecular Sciences. 2024; 25(5):2584. https://doi.org/10.3390/ijms25052584

Chicago/Turabian Style

Bua, Silvia, Alessandro Bonardi, Georgiana Ramona Mük, Alessio Nocentini, Paola Gratteri, and Claudiu T. Supuran. 2024. "Benzothiadiazinone-1,1-Dioxide Carbonic Anhydrase Inhibitors Suppress the Growth of Drug-Resistant Mycobacterium tuberculosis Strains" International Journal of Molecular Sciences 25, no. 5: 2584. https://doi.org/10.3390/ijms25052584

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop